3u88 Citations

The same pocket in menin binds both MLL and JUND but has opposite effects on transcription.

Nature 482 542-6 (2012)
Related entries: 3u84, 3u85, 3u86

Cited: 176 times
EuropePMC logo PMID: 22327296

Abstract

Menin is a tumour suppressor protein whose loss or inactivation causes multiple endocrine neoplasia 1 (MEN1), a hereditary autosomal dominant tumour syndrome that is characterized by tumorigenesis in multiple endocrine organs. Menin interacts with many proteins and is involved in a variety of cellular processes. Menin binds the JUN family transcription factor JUND and inhibits its transcriptional activity. Several MEN1 missense mutations disrupt the menin-JUND interaction, suggesting a correlation between the tumour-suppressor function of menin and its suppression of JUND-activated transcription. Menin also interacts with mixed lineage leukaemia protein 1 (MLL1), a histone H3 lysine 4 methyltransferase, and functions as an oncogenic cofactor to upregulate gene transcription and promote MLL1-fusion-protein-induced leukaemogenesis. A recent report on the tethering of MLL1 to chromatin binding factor lens epithelium-derived growth factor (LEDGF) by menin indicates that menin is a molecular adaptor coordinating the functions of multiple proteins. Despite its importance, how menin interacts with many distinct partners and regulates their functions remains poorly understood. Here we present the crystal structures of human menin in its free form and in complexes with MLL1 or with JUND, or with an MLL1-LEDGF heterodimer. These structures show that menin contains a deep pocket that binds short peptides of MLL1 or JUND in the same manner, but that it can have opposite effects on transcription. The menin-JUND interaction blocks JUN N-terminal kinase (JNK)-mediated JUND phosphorylation and suppresses JUND-induced transcription. In contrast, menin promotes gene transcription by binding the transcription activator MLL1 through the peptide pocket while still interacting with the chromatin-anchoring protein LEDGF at a distinct surface formed by both menin and MLL1.

Reviews - 3u88 mentioned but not cited (3)

Articles - 3u88 mentioned but not cited (7)



Reviews citing this publication (53)

  1. Epigenetic modifications of histones in cancer. Zhao Z, Shilatifard A. Genome Biol 20 245 (2019)
  2. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Thakker RV. Mol Cell Endocrinol 386 2-15 (2014)
  3. Menin: a scaffold protein that controls gene expression and cell signaling. Matkar S, Thiel A, Hua X. Trends Biochem Sci 38 394-402 (2013)
  4. Targeting protein-protein interaction by small molecules. Jin L, Wang W, Fang G. Annu Rev Pharmacol Toxicol 54 435-456 (2014)
  5. The language of chromatin modification in human cancers. Zhao S, Allis CD, Wang GG. Nat Rev Cancer 21 413-430 (2021)
  6. Regulation of histone H3K4 methylation in brain development and disease. Shen E, Shulha H, Weng Z, Akbarian S. Philos Trans R Soc Lond B Biol Sci 369 20130514 (2014)
  7. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. Kamilaris CDC, Stratakis CA. Front Endocrinol (Lausanne) 10 339 (2019)
  8. Genetics of parathyroid tumours. Thakker RV. J Intern Med 280 574-583 (2016)
  9. In focus: MLL-rearranged leukemia. de Boer J, Walf-Vorderwülbecke V, Williams O. Leukemia 27 1224-1228 (2013)
  10. Multiple Endocrine Neoplasia: Genetics and Clinical Management. Norton JA, Krampitz G, Jensen RT. Surg Oncol Clin N Am 24 795-832 (2015)
  11. Therapeutic implications of menin inhibition in acute leukemias. Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Leukemia 35 2482-2495 (2021)
  12. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Pieterman CR, Conemans EB, Dreijerink KM, de Laat JM, Timmers HT, Vriens MR, Valk GD. Endocr Relat Cancer 21 R121-42 (2014)
  13. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Li BE, Ernst P. Exp Hematol 42 995-1012 (2014)
  14. Multiple endocrine neoplasia type 1. Agarwal SK. Front Horm Res 41 1-15 (2013)
  15. The future: genetics advances in MEN1 therapeutic approaches and management strategies. Agarwal SK. Endocr Relat Cancer 24 T119-T134 (2017)
  16. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. Dreijerink KMA, Timmers HTM, Brown M. Endocr Relat Cancer 24 T135-T145 (2017)
  17. Current and emerging therapies for PNETs in patients with or without MEN1. Frost M, Lines KE, Thakker RV. Nat Rev Endocrinol 14 216-227 (2018)
  18. Chemical Inhibition of Protein Methyltransferases. Schapira M. Cell Chem Biol 23 1067-1076 (2016)
  19. Computer-Aided Drug Design in Epigenetics. Lu W, Zhang R, Jiang H, Zhang H, Luo C. Front Chem 6 57 (2018)
  20. MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics. Schernthaner-Reiter MH, Trivellin G, Stratakis CA. Neuroendocrinology 103 18-31 (2016)
  21. Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old. Falchetti A. F1000Res 6 F1000 Faculty Rev-73 (2017)
  22. Why are so many MLL lysine methyltransferases required for normal mammalian development? Crump NT, Milne TA. Cell Mol Life Sci 76 2885-2898 (2019)
  23. Epigenetic regulation by the menin pathway. Feng Z, Ma J, Hua X. Endocr Relat Cancer 24 T147-T159 (2017)
  24. Transcriptional activation by MLL fusion proteins in leukemogenesis. Yokoyama A. Exp Hematol 46 21-30 (2017)
  25. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases. Wang Z, Patel DJ. Q Rev Biophys 46 349-373 (2013)
  26. The many facets of MLL1 regulation. Zhang P, Bergamin E, Couture JF. Biopolymers 99 136-145 (2013)
  27. Menin as a hub controlling mixed lineage leukemia. Thiel AT, Huang J, Lei M, Hua X. Bioessays 34 771-780 (2012)
  28. Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Mercher T, Schwaller J. Front Pediatr 7 401 (2019)
  29. Epigenetic regulation in the tumorigenesis of MEN1-associated endocrine cell types. Iyer S, Agarwal SK. J Mol Endocrinol 61 R13-R24 (2018)
  30. Endocrine neoplasms in familial syndromes of hyperparathyroidism. Li Y, Simonds WF. Endocr Relat Cancer 23 R229-47 (2016)
  31. Recent Topics Around Multiple Endocrine Neoplasia Type 1. Marx SJ. J Clin Endocrinol Metab 103 1296-1301 (2018)
  32. Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective. Marx SJ, Goltzman D. J Bone Miner Res 34 22-37 (2019)
  33. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches. Stevenson M, Lines KE, Thakker RV. Endocrinol Metab Clin North Am 47 525-548 (2018)
  34. The MLL/SET family and haematopoiesis. Antunes ETB, Ottersbach K. Biochim Biophys Acta Gene Regul Mech 1863 194579 (2020)
  35. Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis. Poreba E, Lesniewicz K, Durzynska J. Int J Mol Sci 21 E9340 (2020)
  36. MENIN loss as a tissue-specific driver of tumorigenesis. Li JWY, Hua X, Reidy-Lagunes D, Untch BR. Mol Cell Endocrinol 469 98-106 (2018)
  37. Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives. Khatami F, Tavangar SM. Biomark Insights 13 1177271918785129 (2018)
  38. Animal models of MEN1. Mohr H, Pellegata NS. Endocr Relat Cancer 24 T161-T177 (2017)
  39. Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Ballabio E, Milne TA. Mol Cell Oncol 1 e955330 (2014)
  40. Hyperplasia in glands with hormone excess. Marx SJ. Endocr Relat Cancer 23 R1-14 (2016)
  41. Epigenetics and blood disorders. Scholz B, Marschalek R. Br J Haematol 158 307-322 (2012)
  42. Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges. Yoder KE, Rabe AJ, Fishel R, Larue RC. Front Mol Biosci 8 662331 (2021)
  43. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia. Ozyerli-Goknar E, Nizamuddin S, Timmers HTM. ChemMedChem 16 1391-1402 (2021)
  44. A Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology. Ehrlich L, Hall C, Meng F, Lairmore T, Alpini G, Glaser S. Gene Expr 17 251-263 (2017)
  45. RNA Polymerase II-Dependent Transcription Initiated by Selectivity Factor 1: A Central Mechanism Used by MLL Fusion Proteins in Leukemic Transformation. Yokoyama A. Front Genet 9 722 (2018)
  46. Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system. Yokoyama A. Cancer Sci 112 3935-3944 (2021)
  47. Pathological Features of Tumors of the Nervous System in Hereditary Cancer Predisposition Syndromes: A Review. Tadros S, Kondrashov A, Namagiri S, Chowdhury A, Banasavadi-Siddegowda YK, Ray-Chaudhury A. Neurosurgery 89 343-363 (2021)
  48. Role of the MOZ/MLL-mediated transcriptional activation system for self-renewal in normal hematopoiesis and leukemogenesis. Yokoyama A. FEBS J 289 7987-8002 (2022)
  49. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. Markouli M, Strepkos D, Piperi C. Int J Mol Sci 23 13657 (2022)
  50. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers. Shi Q, Xu M, Kang Z, Zhang M, Luo Y. Molecules 28 3026 (2023)
  51. The role of menin in bone pathology. Gorbacheva A, Eremkina A, Goliusova D, Krupinova J, Mokrysheva N. Endocr Connect 11 e210494 (2022)
  52. Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome. Ruggeri RM, Benevento E, De Cicco F, Grossrubatscher EM, Hasballa I, Tarsitano MG, Centello R, Isidori AM, Colao A, Pellegata NS, Faggiano A. Endocrine 82 480-490 (2023)
  53. Pituitary Tumorigenesis-Implications for Management. Vamvoukaki R, Chrysoulaki M, Betsi G, Xekouki P. Medicina (Kaunas) 59 812 (2023)

Articles citing this publication (113)